- LXRP
CEO Chris Bunka explained in the interview that proprietary technology can
save 60,000 lives annually if consumption habits of even one percent of
smokers worldwide change
- CEO
Clips videos are featured on business sites including BNN
Bloomberg, Thomson Reuters, Yahoo! Finance and Stockhouse.com
- Bunka
went on to described LXRP’s growing patent portfolio and noted that
ingesting rather than inhaling, using DehydraTECH technology, could be a
lifesaver
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO
Chris Bunka sought to raise awareness of LXRP in the financial community as he
appeared, March 23-24, on CEO Clips via YouTube. In the
video, Bunka explained the benefits of DehydraTECH technology, noting that
ingesting drugs and molecules is healthier than inhaling them, and doing so
could be a lifesaver for smokers around the world.
CEO Clips boasts the largest library of publicly
traded CEO videos broadcast in the United States and Canada on national TV and
on 15 business sites, such as BNN Bloomberg, Yahoo! Finance, Thomson Reuters,
Stockhouse.com and others.
“Lexaria Bioscience has the actual opportunity of changing
the world,” Bunka said in the video (http://ibn.fm/keHWB). “We can do it through saving lives,
making health improvements for any number of people who are injecting any
number of drugs or molecules like pain relief, cannabinoids or nicotine.
Everybody knows that smoking is not healthy. Our technology allows for the
delivery of drug molecules like cannabinoids or nicotine through ingestible
means, things that you swallow. It could be a pill, a syrup or a cup of coffee.
That technology, which is called DehydraTECH, is optimized to carry that drug
across the intestinal wall and get more of it to your bloodstream more quickly
than it otherwise could.”
He added that LXRP has tested DehydraTECH in vitro and in
vivo in human clinical studies. Bunka further explained, “We actually have
seven different R&D projects that we are launching in the first half of
2019. We’re also continuing to work on our patent portfolio. We have ten
patents granted already and over 50 more that are pending. If we are able to
help change the consumption habits of even one percent of the global
marketplace who smoke we could save 60,000 lives a year.”
Based in British Columbia, Canada, LXRP is a biotechnology
company and drug-delivery platform innovator, and DehydraTECH is the company’s
proprietary absorption technology platform. LXRP holds a patent for oral
delivery of all cannabinoids and has a growing IP portfolio that includes 10
patents granted in the United States and Australia, and more than 50 patent
applications worldwide across 10 patent families.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
